Table 3

Associated factors with LON in RA

Risk factorPatients with neutropenia (n=25)Patients without neutropenia (n=1950)p Value
Value mean
(SD) or %
Proportion of
available data
per outcome
Value mean
(SD) or %
Proportion of
available data
per outcome
Age (years)53±9100%58±1397%0.02
Sex: female24100%1537100%0.03
Disease duration (years)14±8100%16±1096%0.32
Rheumatoid factor77%88%77%83%0.99
Anti-CCP81%88%74%70%0.62
Previous treatment with anti-TNFα68%100%78%86%0.67
Concomitant synthetic DMARD72%100%65.8%97%0.7
Concomitant prednisone64%100%79%96%0.08
Number of previous synthetic DMARD3±1100%3±197%0.96
DAS28ESR5±188%6±185%0.67
Number of previous treatments with anti-TNFα1±1100%2±197%0.14
Dose of prednisone (mg/day)6.3±7.2100%9.8±995%0.08
Serum γ globulin13±776%12±861%0.61
Serum IgG levels15±656%12±453%1
  • CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic drugs; LON, late-onset neutropenia; RA, rheumatoid arthritis; TNF, tumour necrosis factor.